A detailed history of Lsv Asset Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Lsv Asset Management holds 630,800 shares of HALO stock, worth $30 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
630,800
Previous 613,800 2.77%
Holding current value
$30 Million
Previous $32.1 Million 12.35%
% of portfolio
0.08%
Previous 0.07%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $872,100 - $1.1 Million
17,000 Added 2.77%
630,800 $36.1 Million
Q2 2024

Aug 06, 2024

BUY
$37.81 - $52.4 $5.75 Million - $7.96 Million
152,000 Added 32.91%
613,800 $32.1 Million
Q1 2024

May 06, 2024

SELL
$33.68 - $41.95 $20,208 - $25,170
-600 Reduced 0.13%
461,800 $18.8 Million
Q4 2023

Feb 06, 2024

BUY
$33.32 - $42.1 $15.4 Million - $19.5 Million
462,400 New
462,400 $17.1 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Lsv Asset Management Portfolio

Follow Lsv Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lsv Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Lsv Asset Management with notifications on news.